[PDF][PDF] 多靶点药物治疗前列腺癌研究进展
吴萌， 谢永丽， 岑山， 周金明 - 中国医药生物技术, 2016 - cmbp.net.cn
前列腺癌是男性群体中常见癌症, 在所有癌症种类中, 其致死率位列第六[1].
治疗早期前列腺癌常用外科手术摘除和放射疗法然后辅以药物治疗, 但是对于去势性抵抗前列腺 …
治疗早期前列腺癌常用外科手术摘除和放射疗法然后辅以药物治疗, 但是对于去势性抵抗前列腺 …
[PDF][PDF] 分子靶向治疗在前列腺癌中的研究进展
田俊波， 董自强， 曾文， 梁云 - 现代生物医学进展, 2015 - biomed.cnjournals.com
前列腺癌是目前在全球男性中第二位最常见的肿瘤, 其在恶性肿瘤死亡率中排名第六位[1].
在发病率方面, 我国虽然不及西方国家, 但是随着生活水平和诊疗技术的提高 …
在发病率方面, 我国虽然不及西方国家, 但是随着生活水平和诊疗技术的提高 …
Recent advances in the molecular targeted drugs for prostate cancer
P Gao, T Li, K Zhang, G Luo - International Urology and Nephrology, 2023 - Springer
Abstract Context Prostate cancer (PCa) is the second largest male tumor in the world and
one of the most common malignant tumors in the urinary system. In recent years, the …
one of the most common malignant tumors in the urinary system. In recent years, the …
Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer
PP Singh, S Joshi, PJ Russell, ND Verma, X Wang… - Clinical Cancer …, 2011 - AACR
Purpose: Stemming from its inherent heterogeneity, single-agent treatments are essentially
ineffective against castration-resistant prostate cancer (CRPC). Thus, clinically relevant …
ineffective against castration-resistant prostate cancer (CRPC). Thus, clinically relevant …